Blueprint Medicines Announces Publication in The Lancet Oncology
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
Medicamentos actuales y emergentes “Existen muchas opciones terapéuticas disponibles, pero sigue siendo un desafío hacer coincidir el medicamento correcto con el paciente correcto” Recuerdo en mi memoria ... es junio de 2016, y acabo [...]
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.
Many GIST patients around the world struggle with getting the treatment they need to survive and thrive. Arun Krishnan’s story illustrates how collaboration between patient groups and doctors across the globe can affect patient survival.
Senior Scientific Director Pete Knox reports on current and emerging GIST treatments and the mutations they address. New research in GIST is happening, and there may be even more therapies around the corner.
Being diagnosed with a rare cancer like GIST can make finding resources more challenging. While this is not an exhaustive list of resources available, these organizations can provide a wealth of information and assistance.
Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Subscribe to the LRG Newsletter 2023View December NewsletterView August Newsletter- GAD Highlights, Life Fest 2024 news & more!View April Newsletter 2022 View December 2022 Newsletter PDF Focus on GDOLs CTOS Sheds [...]
Many people love the warm sun, beaches, and gardens, but along with those beautiful summer days comes the threat of sun damage. What does this mean for GIST patients?
If you didn't find what you were looking for, try a new search!